A commercially available blood test has shown high levels of accuracy in detecting Alzheimer’s, even in its early stages, boosting the prospects of early diagnosis for sufferers of the neurodegenerative disease.
Alzheimer’s, a type of dementia, is currently diagnosed through invasive and expensive tests such as a lumbar puncture to release spinal fluid or through a tomographic scan. Patients can face long waits for these procedures.
But according to a peer-reviewed study by Sweden’s Gothenburg university, a blood test known as the p-tau217 immunoassay yielded “high accuracy” in identifying tau, one of the proteins associated with a toxic build-up in the brain that can cause Alzheimer’s, across all 786 patients in the trial.
您已阅读24%（732字），剩余76%（2285字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。